title: Comment on: Efficacy and safety of daptomycin for the treatment of infectious disease: a meta-analysis based on randomized controlled trials.
authors.affiliation: Cubist Pharmaceuticals, 65 Hayden Avenue, Lexington, MA 02421, USA michele.potashman@cubist.com.
authors.forename: Michele H
authors.initials: MH
authors.lastname: Potashman
authors.affiliation: Cubist Pharmaceuticals, 65 Hayden Avenue, Lexington, MA 02421, USA Northeastern University, 360 Huntington Avenue, Boston, MA 02115, USA.
authors.forename: Danielle N
authors.initials: DN
authors.lastname: Formella
authors.affiliation: Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ 07936, USA.
authors.forename: Kamal
authors.initials: K
authors.lastname: Hamed
authors.affiliation: Cubist Pharmaceuticals, 65 Hayden Avenue, Lexington, MA 02421, USA.
authors.forename: John F
authors.initials: JF
authors.lastname: Mohr
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D003141:Communicable Diseases / Q000188:drug therapy*; D017576:Daptomycin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male
chemical_list: D000900:Anti-Bacterial Agents; D017576:Daptomycin
keywords: CAP; SAB; bacteraemia; cSSSIs; complicated skin and skin structure infections; meta-analysis; pneumonia